4-Amino-5-[(1-carboxy-2-sulfanylethyl)amino]-5-oxopentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Amino-5-[(1-carboxy-2-sulfanylethyl)amino]-5-oxopentanoic acid
• 化学式: C₈H₁₄N₂O₅S
• 分子量: 250.27
• InChiKey: PABVKUJVLNMOJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  131
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• [EN] COMPOSITIONS COMPRISING SELENIUM AND USE OF SAME FOR THE TREATMENT AND PREVENTION OF DISEASE OR CONDITIONS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION<br/>[FR] COMPOSITIONS COMPRENANT DU SÉLÉNIUM ET UTILISATION DE CELLES-CI POUR LE TRAITEMENT ET LA PRÉVENTION DE MALADIE OU D'ÉTATS ASSOCIÉS AVEC UN DYSFONCTIONNEMENT MITOCHONDRIAL
  申请人：ALLTECH INC

  公开号：WO2014144776A1

  公开（公告）日：2014-09-18

  The present application relates to compositions comprising selenium (e.g., selenium enriched yeast and selenium containing compounds obtained or derived therefrom) and methods of using the same to treat and inhibit obesity, diabetes and related conditions. In particular, the present application provides compositions comprising selenium enriched yeast (e.g., selenium enriched yeast comprising 2% or less inorganic selenium), selenium containing compounds present therein and/or derived therefrom, and methods of using the same to enhance mitochondrial activity and function (e.g., in skeletal muscle and liver) in a subject (e.g., as a therapeutic and/or prophylactic treatment for diabetes, obesity and related conditions).

  本申请涉及含硒的组合物（例如，富硒酵母和从中获得或衍生的含硒化合物）及其用于治疗和抑制肥胖、糖尿病和相关疾病的方法。具体而言，本申请提供了含硒富集酵母的组合物（例如，含有2％或更少无机硒的富硒酵母），其中含有或从中衍生的含硒化合物，并使用它们的方法来增强线粒体活性和功能（例如，在骨骼肌和肝脏中）以治疗和/或预防糖尿病、肥胖和相关疾病。
• [EN] GOLD COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSÉS D'OR ET LEUR UTILISATION DANS LE CADRE D'UNE THÉRAPIE
  申请人：AUSPHERIX LTD

  公开号：WO2018220171A1

  公开（公告）日：2018-12-06

  Compound of formula (I) and pharmaceutically acceptable salts and solvates thereof are described, wherein: Px selected from (P1), (P2) or (P3); The compounds are useful in the prevention or treatment of a bacterial infection.

  描述了化合物的公式（I）及其药用可接受的盐和溶剂化合物，其中：Px选自（P1）、（P2）或（P3）；这些化合物在预防或治疗细菌感染方面是有用的。
• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• [EN] [1,5]-DIAZOCIN DERIVATIVES<br/>[FR] DÉRIVÉS DE [1,5]-DIAZOCINE
  申请人：MELLITECH

  公开号：WO2011058193A1

  公开（公告）日：2011-05-19

  The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound for manufacturing a medicament. In particular the medicament and the pharmaceutical composition are intended to treat diseases linked with insulin regulation problems, such as diabetes. This invention aims also to methods for treating or preventing such diseases.

  本发明涉及公式(I)的化合物组合物，特别是药物组合物和至少包含一种公式(I)化合物的药物。本发明还涉及使用这种化合物制造药物。特别是药物和药物组合物旨在治疗与胰岛素调节问题相关的疾病，例如糖尿病。本发明还旨在提供治疗或预防这种疾病的方法。
• [EN] PROCESS FOR SYNTHESIZING ERGOTHIONEINE AND RELATED COMPOUNDS<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE L'ERGOTHIONÉINE ET DE COMPOSÉS APPARENTÉS
  申请人：UNIV CAPE TOWN

  公开号：WO2016046618A1

  公开（公告）日：2016-03-31

  The invention provides a process for synthesising a compound of formula (V) wherein: formula (z) or a physiologically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof. The process utilizes a /V-benzyl protected histidine rather than the unprotected form of histidine. The process of the invention comprises the steps of: (a) deprotecting a /V-benzyl protected histidine of formula 11 to form A/-benzyl histidine of formula 12; (b) converting compound 12 to (S)-3-(1 -benzyl-1 H-imidazol-4-yl)-2-(dimethylamino)propanoic acid of formula 13; (c) converting compound 13 to (2S)-N,N,N-2-trimethylethanaminium-3-(1 -benzyl- 1H-imidazol-4-yl)propanoic acid of formula 14; (d) brominating the imidazole ring of the compound of formula 14 to form 5-bromohercynine lactone (reactive intermediate); and (e) converting the 5-bromohercynine lactone of step (d) to (p-amino-p- carboxyethyl)ergothioneine sulfide of formula 15. The process optionally further includes one of steps (f) to (h): (f) converting the compound of formula 15 to a sulfoxide; (g) converting the compound of formula 15 to a sulfone; or (h) converting the compound of formula 15 to ergothioneine (ESH).

  本发明提供了一种合成式（V）化合物的方法，其中：公式（z）或其生理可接受的盐、变构体、立体异构体或立体异构体混合物。该方法使用/V-苄基保护组氨酸代替未保护的组氨酸。本发明的方法包括以下步骤：（a）去保护公式11的/V-苄基保护组氨酸，形成公式12的A/-苄基组氨酸；（b）将化合物12转化为公式13的（S）-3-（1-苄基-1H-咪唑-4-基）-2-（二甲氨基）丙酸；（c）将化合物13转化为公式14的（2S）-N，N，N-2-三甲基乙酰胺-3-（1-苄基-1H-咪唑-4-基）丙酸；（d）溴化公式14化合物中的咪唑环，形成5-溴赫尔岑酮（反应中间体）；和（e）将步骤（d）中的5-溴赫尔岑酮转化为公式15的（对氨基-对羧乙基）麦角硫氨酸硫醚。该方法还可选地进一步包括步骤（f）至（h）中的一项：（f）将公式15的化合物转化为亚砜；（g）将公式15的化合物转化为磺酰；或（h）将公式15的化合物转化为麦角硫氨酸（ESH）。